GI Innovation, Inc. (KOSDAQ:358570)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,140
+850 (5.56%)
At close: Feb 27, 2026
4.87%
Market Cap 1.03T
Revenue (ttm) 338.09M
Net Income (ttm) -51.99B
Shares Out 64.09M
EPS (ttm) -976.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,118,730
Average Volume 677,548
Open 15,300
Previous Close 15,290
Day's Range 15,260 - 16,270
52-Week Range 11,240 - 24,900
Beta 0.15
RSI 57.03
Earnings Date n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101/GI-102, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; GI-108, an metabolic immunotherapy oncology agent; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The co... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 358570
Full Company Profile

Financial Performance

In 2024, GI Innovation's revenue was 24.28 million, a decrease of -99.54% compared to the previous year's 5.32 billion. Losses were -58.78 billion, 5.93% more than in 2023.

Financial Statements

News

There is no news available yet.